Stephan Stilgenbauer
Stephan Stilgenbauer
Professor of Medicine, Ulm University, Ulm, Germany
Verified email at - Homepage
Cited by
Cited by
Genomic aberrations and survival in chronic lymphocytic leukemia
H Döhner, S Stilgenbauer, A Benner, E Leupolt, A Kröber, L Bullinger, ...
New England Journal of Medicine 343 (26), 1910-1916, 2000
Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial
M Hallek, K Fischer, G Fingerle-Rowson, AM Fink, R Busch, J Mayer, ...
The Lancet 376 (9747), 1164-1174, 2010
Idelalisib and rituximab in relapsed chronic lymphocytic leukemia
RR Furman, JP Sharman, SE Coutre, BD Cheson, JM Pagel, P Hillmen, ...
New England Journal of Medicine 370 (11), 997-1007, 2014
Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions
V Goede, K Fischer, R Busch, A Engelke, B Eichhorst, CM Wendtner, ...
New England Journal of Medicine 370 (12), 1101-1110, 2014
Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma
ML Wang, S Rule, P Martin, A Goy, R Auer, BS Kahl, W Jurczak, ...
New England Journal of Medicine 369 (6), 507-516, 2013
iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL
M Hallek, BD Cheson, D Catovsky, F Caligaris-Cappio, G Dighiero, ...
Blood, The Journal of the American Society of Hematology 131 (25), 2745-2760, 2018
Matrix‐based comparative genomic hybridization: biochips to screen for genomic imbalances
S Solinas‐Toldo, S Lampel, S Stilgenbauer, J Nickolenko, A Benner, ...
Genes, chromosomes and cancer 20 (4), 399-407, 1997
Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib
JA Woyach, RR Furman, TM Liu, HG Ozer, M Zapatka, AS Ruppert, L Xue, ...
New England Journal of Medicine 370 (24), 2286-2294, 2014
Mutations driving CLL and their evolution in progression and relapse
DA Landau, E Tausch, AN Taylor-Weiner, C Stewart, JG Reiter, J Bahlo, ...
Nature 526 (7574), 525-530, 2015
V H mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia
A Kröber, T Seiler, A Benner, L Bullinger, E Brückle, P Lichter, ...
Blood, The Journal of the American Society of Hematology 100 (4), 1410-1416, 2002
p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias
H Dohner, K Fischer, M Bentz, K Hansen, A Benner, G Cabot, D Diehl, ...
Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia
BF Eichhorst, R Busch, G Hopfinger, R Pasold, M Hensel, C Steinbrecher, ...
Blood 107 (3), 885-891, 2006
Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study
S Stilgenbauer, B Eichhorst, J Schetelig, S Coutre, JF Seymour, T Munir, ...
The lancet oncology 17 (6), 768-778, 2016
Venetoclax and obinutuzumab in patients with CLL and coexisting conditions
K Fischer, O Al-Sawaf, J Bahlo, AM Fink, M Tandon, M Dixon, S Robrecht, ...
New England Journal of Medicine 380 (23), 2225-2236, 2019
Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial
K Fischer, J Bahlo, AM Fink, V Goede, CD Herling, P Cramer, ...
Blood, The Journal of the American Society of Hematology 127 (2), 208-215, 2016
Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia
WG Wierda, TJ Kipps, J Mayer, S Stilgenbauer, CD Williams, A Hellmann, ...
Journal of Clinical Oncology 28 (10), 1749-1755, 2010
From pathogenesis to treatment of chronic lymphocytic leukaemia
T Zenz, D Mertens, R Küppers, H Döhner, S Stilgenbauer
Nature Reviews Cancer 10 (1), 37-50, 2010
TP53 Mutation and Survival in Chronic Lymphocytic Leukemia
T Zenz, B Eichhorst, R Busch, T Denzel, S Häbe, D Winkler, A Bühler, ...
Journal of Clinical Oncology 28 (29), 4473-4479, 2010
First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10 …
B Eichhorst, AM Fink, J Bahlo, R Busch, G Kovacs, C Maurer, E Lange, ...
The lancet oncology 17 (7), 928-942, 2016
Hemicraniectomy in older patients with extensive middle-cerebral-artery stroke
E Jüttler, A Unterberg, J Woitzik, J Bösel, H Amiri, OW Sakowitz, ...
New England Journal of Medicine 370 (12), 1091-1100, 2014
The system can't perform the operation now. Try again later.
Articles 1–20